Stephanie D. Davis

Dr. Stephanie D. Davis


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SDStephanie D. Davis
Stephanie D. Davis
LFLynn A. Fordham
Lynn A. Fordham
ABAlan S. Brody
Alan S. Brody
TNTerry L. Noah
Terry L. Noah
GRGeorge Z. Retsch-Bogart
George Z. Retsch-Bogart
MLMargaret W. Leigh
Margaret W. Leigh
Rationale: Detecting and tracking early cystic fibrosis (CF) lung disease are difficult due to lack of sensitive markers of airway dysfunction. Objectives: The goals were to detect regional distribution of airway disease through high-resolution computed tomography, correlate abnormalities to lower airway inflammation/infection, and compare computed tomography findings before and after intravenous antibiotic therapy in children with CF younger than 4 years experiencing a pulmonary exacerbation. Methods: High-resolution computed tomography was performed in 17 children scheduled for bronchoscopy. The radiologist identified the lobes with the “greatest” and “least” disease based on computed tomography, and bronchoalveolar lavage was performed in these areas. In 13 subjects, imaging was repeated after antibiotic completion. Modified Brody scores were assigned by two radiologists. Measurements and Main Results: The lobe with greatest disease was predominantly localized to the right and had higher modified Brody scores, indicating more severe abnormalities (p < 0.01), compared with the lobe with least disease. The total modified Brody score (p < 0.01), hyperinflation subscore (p < 0.01), and bronchial dilatation/bronchiectasis subscore (p < 0.01) improved after antibiotics and intensified airway clearance. Interleukin-8 levels (p < 0.01) and % neutrophils (p = 0.04) were increased in the lobe with greatest disease compared with the lobe with least disease. Conclusions: These results indicate that, in young children with CF experiencing a pulmonary exacerbation, computed tomography detects regional differences in airway inflammation, may be a sensitive outcome to evaluate therapeutic interventions, and identifies early lung disease as being more prominent on the right.

1 December 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SDStephanie D. Davis
Stephanie D. Davis
MRMargaret Rosenfeld
Margaret Rosenfeld
GKGwendolyn S. Kerby
Gwendolyn S. Kerby
LBLyndia Brumback
Lyndia Brumback
MKMargaret H. Kloster
Margaret H. Kloster
RCRobert G. Castile
Robert G. Castile
Rationale: The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures. Objectives: To evaluate safety, feasibility, and ability to detect abnormalities in lung function of serial pulmonary function tests (PFTs) in infants with CF. Methods: Multicenter observational study using a commercial device, rigorous training, ongoing quality control, and over-reading of data by an independent panel. Raised volume rapid thoracoabdominal compression technique and plethysmography were performed at enrollment and at 6 and 12 months, with an additional 1-month reproducibility visit. Measurements and Main Results: A total of 342 procedures were performed in 100 infants with CF at 10 centers. FRC measurements were acceptable at a higher proportion of study visits (89%) than raised volume (72%) or fractional lung volume (68%) measurements. Average Z scores for many parameters differed significantly from historical control values. Mean (95% confidence interval) Z scores were: −0.52 (−0.78 to −0.25) for forced expiratory flow at 75% (FEF75) for FVC; 1.92 (1.39–2.45) for FRC; 1.22 (0.68–1.76) for residual volume; 0.87 (0.60–1.13) for FRC/total lung capacity; and 0.66 (0.27–1.06) for residual volume/total lung capacity. For future multicenter clinical trials using infant PFTs as primary endpoints, minimum detectable treatment effects are presented for several sample sizes. Conclusions: In this 10-center study, key PFT measures were significantly different in infants with CF than in historical control subjects. However, infant PFTs do not yet appear ready as primary efficacy endpoints for multicenter clinical trials, particularly at inexperienced sites, based on acceptability rates, variability, and potentially large sample sizes required to detect reasonable treatment effects.

26 March 2008 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DBDavid E. Brown
David E. Brown
JPJessica E. Pittman
Jessica E. Pittman
MLMargaret W. Leigh
Margaret W. Leigh
LFLynn Fordham
Lynn Fordham
SDStephanie D. Davis
Stephanie D. Davis

1 August 2007 in Proceedings of the American Thoracic Society
Verified
Journal Article
Closed access
SDStephanie D. Davis
Stephanie D. Davis
ABAlan S. Brody
Alan S. Brody
MEMary J. Emond
Mary J. Emond
LBLyndia C. Brumback
Lyndia C. Brumback
MRMargaret Rosenfeld
Margaret Rosenfeld
The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lung disease in very young children with CF was hampered by a lack of reproducible measures of lung function or lung pathology. Over the past 10 years, significant progress has led to physiologic, anatomic, and bronchoscopic measures that may serve as endpoints for future intervention trials. These endpoints include infant and preschool lung function testing, computed tomography of the chest, and bronchoalveolar lavage markers of inflammation and infection. Much progress has occurred in standardizing lung function testing, which is essential for multicenter collaboration. Pulmonary exacerbation has the potential to serve as a clinical endpoint; however, there is currently no standardized definition in children with CF younger than 6 years. Further development of these outcomes measures will enable clinical trials in the youngest CF population with the objective of improving long-term prognosis.

20 April 2009 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
SPStacey L. Peterson-Carmichael
Stacey L. Peterson-Carmichael
WHWilliam T. Harris
William T. Harris
RGRuchika Goel
Ruchika Goel
TNTerry L. Noah
Terry L. Noah
RJRobin Johnson
Robin Johnson
SDStephanie D. Davis
Stephanie D. Davis

15 June 2006 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
JSJohn Saito
John Saito
WHWilliam T. Harris
William T. Harris
JGJonathan Gelfond
Jonathan Gelfond
TNTerry L. Noah
Terry L. Noah
MLMargaret W. Leigh
Margaret W. Leigh
SDStephanie D. Davis
Stephanie D. Davis